GSK (GSK) Expected to Announce Earnings on Wednesday

GSK (NYSE:GSK) is projected to post its quarterly earnings results before the market opens on Wednesday, February 5th. Analysts expect GSK to post earnings of $0.44 per share and revenue of $7.75 billion for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

GSK Price Performance

NYSE:GSK opened at $34.91 on Tuesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK has a 52 week low of $31.72 and a 52 week high of $45.92. The firm’s 50-day simple moving average is $34.07 and its 200 day simple moving average is $37.67. The firm has a market cap of $72.34 billion, a price-to-earnings ratio of 22.67, a P/E/G ratio of 1.38 and a beta of 0.64.

Analyst Ratings Changes

Several equities research analysts recently weighed in on GSK shares. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.